Dasatinib monohydratefeatured
WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#:100230
CAS#:863127-77-9 (hydrate)
Description:Dasatinib, also known as BMS-354825, is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations.
Price and Availability
Dasatinib monohydrate, purity > 99%, is in stock. The same day shipping out after order is received.
Chemical Structure
Theoretical Analysis
MedKoo Cat#: 100230Name: Dasatinib monohydrateCAS#: 863127-77-9 (hydrate)Chemical Formula: C22H28ClN7O3SExact Mass: 487.15572Molecular Weight: 506.02Elemental Analysis: C, 52.22; H, 5.58; Cl, 7.01; N, 19.38; O, 9.49; S, 6.34
Related CAS #:302962-49-8 (free form)863127-77-9 (hydrate)
Synonym:BMS-354825; BMS 354825; BMS354825; Dasatinib; US brand name: Sprycel.
IUPAC/Chemical Name:N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide monohydrate.
InChi Key:XHXFZZNHDVTMLI-UHFFFAOYSA-N
InChi Code:InChI=1S/C22H26ClN7O2S.H2O/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31;/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27);1H2
SMILES Code:O=C(C1=CN=C(NC2=NC(C)=NC(N3CCN(CCO)CC3)=C2)S1)NC4=C(C)C=CC=C4Cl.[H]O[H]
Technical Data
Additional Information
Related CAS#863127-77-9 (Dasatinib monohydrate); 302962-49-8 (Dasatinib).
References
1: Korashy HM, Rahman AF, Kassem MG. Dasatinib.Profiles Drug Subst Excip Relat Methodol. 2014;39:205-37. doi:10.1016/B978-0-12-800173-8.00004-0. Review. PubMed PMID: 24794907.
2: Lindauer M, Hochhaus A. Dasatinib. Recent Results Cancer Res.2014;201:27-65. doi: 10.1007/978-3-642-54490-3_2. Review. PubMed PMID:24756784.
3: Qiu ZY, Xu W, Li JY. Large granular lymphocytosis during dasatinibtherapy. Cancer Biol Ther. 2014 Mar 1;15(3):247-55. doi:10.4161/cbt.27310. Epub 2013 Dec 18. Review. PubMed PMID: 24352048;PubMed Central PMCID: PMC3974824.
4: Nagao T, Takahashi N, Kameoka Y, Noguchi S, Shinohara Y, Ohyagi H,Kume M, Sawada K. Dasatinib-responsive chronic lymphocytic leukemia in apatient treated for coexisting chronic myeloid leukemia. Intern Med.2013;52(22):2567-71. Review. PubMed PMID: 24240798.
5: Paydas S. Dasatinib, large granular lymphocytosis, and pleuraleffusion: useful or adverse effect? Crit Rev Oncol Hematol. 2014Feb;89(2):242-7. doi: 10.1016/j.critrevonc.2013.10.005. Epub 2013 Oct12. Review. PubMed PMID: 24210599.
6: Signorovitch J, Ayyagari R, Reichmann WM, Wu EQ, Chen L. Majormolecular response during the first year of dasatinib, imatinib ornilotinib treatment for newly diagnosed chronic myeloid leukemia: anetwork meta-analysis. Cancer Treat Rev. 2014 Mar;40(2):285-92. doi:10.1016/j.ctrv.2013.09.004. Epub 2013 Sep 17. Review. PubMed PMID:24112812.
7: Eadie LN, Hughes TP, White DL. Interaction of the efflux transportersABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. Clin PharmacolTher. 2014 Mar;95(3):294-306. doi: 10.1038/clpt.2013.208. Epub 2013 Oct9. Review. PubMed PMID: 24107928.
8: Hochhaus A, Kantarjian H. The development of dasatinib as a treatmentfor chronic myeloid leukemia (CML): from initial studies to applicationin newly diagnosed patients. J Cancer Res Clin Oncol. 2013Dec;139(12):1971-84. doi: 10.1007/s00432-013-1488-z. Epub 2013 Aug 13.Review. PubMed PMID: 23942795; PubMed Central PMCID: PMC3825579.
9: Brazzelli V, Grasso V, Borroni G. Imatinib, dasatinib and nilotinib:a review of adverse cutaneous reactions with emphasis on our clinicalexperience. J Eur Acad Dermatol Venereol. 2013 Dec;27(12):1471-80. doi:10.1111/jdv.12172. Epub 2013 Apr 24. Review. PubMed PMID: 23611501.
10: Keating GM, Lyseng-Williamson KA, McCormack PL, Keam SJ. Dasatinib:a guide to its use in chronic myeloid leukemia in the EU. BioDrugs. 2013Jun;27(3):275-9. doi: 10.1007/s40259-013-0024-7. Review. PubMed PMID:23549840.
